OncoMed Pharma provides update on FDZ8-Fc (OMP-54F28) Phase 1 clinical trials; Partial clinical hold formally placed on trials (OMED)
NephroGenex initiates pivotal Phase 3 study with novel treatment to slow progression of diabetic kidney disease (NRX)
Dominion Resrcs states that its policy is not to comment on unusual market activity (DOM)
Red Hat beats by $0.01, beats on revs and Billings (RHT)
Measurement Specialties to be acquired by TE Connectivity (TEL) for $86 cash per share or a total transaction value of ~ $1.7 bln, including assumption of net debt (shares halted) (MEAS)
Jabil Circuit beats by $0.02, beats on revs; guides Q4 EPS in-line, revs in-line; reaffirms FY15 EPS guidance (JBL)
Qiagen receives FDA approval of artus CMV RGQ MDx kit to monitor Cytomegalovirus (CMV.V) viral load in organ transplant patients (QGEN)
Rex Energy initiated with an Outperform at Imperial Capital Target $25. REXX
Aratana Therapeutics doses first patient in study of AT-005 PETX
Symbol | Last Sale | Change | % Change | Share Volume | Market |
---|---|---|---|---|---|
OMED | ▲ | NASDAQ-GS | |||
NRX | ▲ | NASDAQ-CM | |||
DOM | ▼ | NYSE | |||
MEAS | ▲ | NASDAQ-GS | |||
TEL | ▲ | NYSE | |||
RHT | ▲ | NYSE | |||
JBL | ▲ | NYSE | |||
QGEN | ▲ | NASDAQ-GS | |||
REXX | ▲ | NASDAQ-GS | |||
PETX | ▲ | NASDAQ-GM |
No comments:
Post a Comment